GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (NAS:JAZZ) » Definitions » Cyclically Adjusted PB Ratio

JAZZ (Jazz Pharmaceuticals) Cyclically Adjusted PB Ratio : 1.81 (As of May. 12, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-05-12), Jazz Pharmaceuticals's current share price is $103.35. Jazz Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $57.19. Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 1.81.

The historical rank and industry rank for Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

JAZZ' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.71   Med: 5.28   Max: 25.25
Current: 1.71

During the past years, Jazz Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 25.25. The lowest was 1.71. And the median was 5.28.

JAZZ's Cyclically Adjusted PB Ratio is ranked worse than
54.89% of 665 companies
in the Biotechnology industry
Industry Median: 1.47 vs JAZZ: 1.71

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was $67.749. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $57.19 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Jazz Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.28 3.23 3.46 2.40 2.21

Jazz Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.31 1.99 2.05 2.21 2.17

Competitive Comparison of Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=103.35/57.19
=1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jazz Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Jazz Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=67.749/123.4051*123.4051
=67.749

Current CPI (Mar. 2025) = 123.4051.

Jazz Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 23.630 100.573 28.994
201509 25.423 100.274 31.288
201512 26.077 99.676 32.285
201603 26.572 99.676 32.898
201606 27.981 101.072 34.164
201609 28.652 100.274 35.261
201612 31.383 99.676 38.854
201703 33.073 100.374 40.662
201706 36.628 100.673 44.899
201709 41.189 100.474 50.590
201712 45.295 100.075 55.855
201803 46.451 100.573 56.996
201806 47.602 101.072 58.121
201809 50.186 101.371 61.095
201812 47.952 100.773 58.722
201903 47.984 101.670 58.242
201906 52.687 102.168 63.639
201909 53.947 102.268 65.097
201912 55.415 102.068 66.999
202003 50.724 102.367 61.148
202006 56.654 101.769 68.699
202009 60.750 101.072 74.174
202012 65.154 101.072 79.551
202103 66.775 102.367 80.498
202106 67.602 103.364 80.709
202109 64.165 104.859 75.514
202112 64.336 106.653 74.441
202203 57.973 109.245 65.487
202206 51.112 112.779 55.928
202209 43.651 113.504 47.459
202212 48.814 115.436 52.184
202303 52.121 117.609 54.690
202306 55.612 119.662 57.352
202309 55.435 120.749 56.655
202312 60.027 120.749 61.348
202403 58.648 120.990 59.819
202406 60.938 122.318 61.479
202409 69.008 121.594 70.036
202412 67.519 122.439 68.052
202503 67.749 123.405 67.749

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Jazz Pharmaceuticals  (NAS:JAZZ) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Jazz Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Executives
Bruce C Cozadd director, officer: Executive Chairman C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 00000
Robert Iannone officer: EVP, Research & Development 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Patricia Carr officer: VP, Finance& PAO JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Neena M Patil officer: SVP, General Counsel JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Mary Elizabeth Henderson officer: SVP, Technical Operations 3170 PORTER DRIVE, PALO ALTO CA 94304
Jennifer E. Cook director C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080
Mark Douglas Smith director C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Catherine A. Sohn director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Rick E Winningham director 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Heather Ann Mcsharry director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Peter Gray director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Anne Oriordan director HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK
Kenneth W O'keefe director C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603